Search Results for: -trf7pw.html

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 05, 2024 09:10 ET CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (GSK-3β),

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference Read More »

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024

August 20, 2024 09:00 ET CHICAGO and FORT WORTH, Texas, Aug. 20, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President

Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 Read More »

Actuate Therapeutics Announces Closing of Initial Public Offering

August 14, 2024 16:05 ET CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the closing of its previously announced initial public offering of 2,800,000

Actuate Therapeutics Announces Closing of Initial Public Offering Read More »

Actuate Therapeutics Announces Pricing of Initial Public Offering

August 12, 2024 20:27 ET CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of

Actuate Therapeutics Announces Pricing of Initial Public Offering Read More »

2024-ASCO-Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study

Publications /

2024-ASCO-Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study Read More »

2024-ASCO-Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study.

Publications /

2024-ASCO-Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. Read More »